Research Article

Advances in Neonatal Sepsis Detection Using Rapid Molecular Diagnostic Technologies and Biomarkers

Dr. Senthamarai S[1] Dr. Mohanraj P[2] Dr. Archana[3] Ms. Nafrin AZ[4]

[1] Professor & HOD, Microbiology , Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552. senthamarais@maher.ac.in
[2]Professor, General Medicine, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552. mohanraj@maher.ac.in
[3]Professor, Pathology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552. archana@maher.ac.in
[4]Lecturer, Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research. nafrinaz@maher.ac.in

Abstract

Background:
Neonatal sepsis is a life threatening condition and a leading cause of neonatal morbidity and mortality globally. Early diagnosis is still difficult because clinical symptoms are often nonspecific and conventional blood culture methods are time-consuming. Recent advances in rapid molecular diagnostic technologies and biomarker-based approaches have improved timely detection and management of neonatal sepsis.

Objective:
To assess the effectiveness of rapid molecular diagnostic technologies and biomarkers in early detection of neonatal sepsis and their impact on clinical outcomes.

Methodology:
We conducted a prospective observational study in 220 neonates in neonatal intensive care units (NICU). Blood samples were analyzed by molecular diagnostics based on polymerase chain reaction (PCR) and biomarker assays (including C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6). Diagnostic accuracy, detection time and treatment results were examined.

Findings:
Among the enrolled neonates, 68 (30.9%) had a diagnosis of confirmed sepsis. Rapid molecular diagnostics identified pathogens in 4.2 ± 1.1 hours compared to 48–72 hours for conventional cultures. The combined biomarker analysis identified sepsis with a sensitivity of 91.4% and a specificity of 88.7%. Early diagnosis reduced the average delay in starting antibiotics by 42% and survival was 94.1% among neonates diagnosed.

Conclusion:
The early diagnosis of neonatal sepsis is greatly facilitated by rapid molecular diagnostic technologies and the assessment of biomarkers. Including them in neonatal care can assist in early management, better survival outcome and decrease sepsis associated complications.

Keywords: Neonatal Sepsis, Molecular Diagnostics, Biomarkers, Polymerase Chain Reaction, Procalcitonin, C-Reactive Protein, Interleukin-6, Early Detection, Neonatal Intensive Care Unit.

1 Introduction

Neonatal sepsis is still one of the major causes of morbidity and mortality in the neonatal period all over the world especially in the preterm and low-birth-weight infants. Despite significant advances in neonatal intensive care, sepsis still represents a high percentage of neonatal deaths and long-term neurodevelopmental complications. Neonatal sepsis commonly has non-specific clinical manifestations, which make early diagnosis difficult and lead to delays in the initiation of treatment [1]. Accurate and timely detection is therefore the key to improve survival outcome and reduce complications associated with severe infections.

Blood culture has historically been used as the gold standard for the diagnosis of neonatal sepsis. However, the traditional culture-based methods have several drawbacks such as long turnaround time, low sensitivity due to small volume of blood sample, and false-negative results after maternal or neonatal antibiotic exposure [2]. These limitations have created the need for faster and more reliable diagnostic approaches that can identify pathogens early in infection.

The recent advances in molecular diagnostic technology have revolutionized neonatal sepsis detection. Polymerase chain reaction (PCR), real-time PCR, multiplex PCR, and next-generation sequencing are techniques that allow for the rapid detection of bacterial and fungal pathogens directly from blood samples [3]. These methods have a substantial time to diagnosis reduction when compared to conventional cultures and show increased sensitivity in detecting low microbial loads [4]. It has been shown that molecular assays can detect pathogens in hours, allowing earlier antimicrobial intervention and improved clinical decision making [5].

Biomarkers have become useful for early detection of neonatal sepsis in addition to molecular diagnostics. Biomarkers including C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α) reflect host inflammatory response to infection and offer valuable diagnostic clues [6]. Among these, CRP and PCT are widely utilized in clinical practice due to their relatively high sensitivity and specificity for bacterial infection [7].

Studies have shown that no single biomarker is sufficiently accurate diagnostically to reliably rule in or rule out neonatal sepsis. Therefore, the development of assays with combinations of multiple biomarkers and molecular diagnostic tools is increasingly being explored for improvement in diagnostic performance [8]. Integrated approaches of PCR assays and inflammatory biomarkers have shown better sensitivity, specificity and predictive value than conventional methods alone [9].

The advent of precision medicine, omics technologies and machine-learning based diagnostic models has further provided opportunities to improve detection of neonatal sepsis [10]. These innovations may enable personalized therapeutic strategies, reduce unnecessary antibiotic exposure, and improve antimicrobial stewardship in neonatal intensive care units [11]. Thus, it is important to evaluate progress in rapid molecular diagnostics and biomarker-based strategies for improving neonatal sepsis management and outcomes in neonates.

1.1 Objectives

1. To evaluate the effectiveness of rapid molecular diagnostic technologies in the early detection of neonatal sepsis.
2. To assess the diagnostic value of biomarkers in improving the accuracy and timeliness of neonatal sepsis identification and management.

2 Literature review

2.1 Rapid Molecular Diagnostic Technologies in Neonatal Sepsis

Recent advances in molecular diagnostic technologies have revolutionized the early diagnosis of neonatal sepsis. Polymerase chain reaction (PCR), multiplex PCR and next generation sequencing (NGS) can detect bacterial and fungal pathogens rapidly within few hours, compared to conventional blood cultures that often require 48–72 hours [12]. Improved sensitivity and specificity have been achieved with these technologies, leading to earlier clinical interventions and reduced diagnostic delays [13].

2.2 Biomarkers for Early Sepsis Identification

Biomarkers are necessary to detect neonatal sepsis before clinical symptoms become severe. The most studied markers are procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6). Recent studies have demonstrated that increased PCT and IL-6 levels have good predictive value for early-onset neonatal sepsis and support decisions for early antimicrobial therapy [14]. The combination of multiple biomarkers increases the diagnostic accuracy and reduces false positive results [15].

2.3 Integrated Diagnostic Approaches

Recent studies highlight the combination of molecular diagnostics with biomarker analysis to enhance sepsis detection. Studies performed in the years 2023-2025 demonstrated that combined approaches provide sensitivity higher than 90% and significantly improve the rate of pathogen identification [16]. These strategies allow personalized treatment and optimal antibiotic stewardship in neonatal intensive care units (NICUs) [17].

2.4 Trends and Gaps on Emerging Research

Artificial intelligence, machine learning and multi-omics technologies are emerging as promising tools for the diagnosis of neonatal sepsis. Such innovations allow for predictive modeling and real-time clinical decision support [7]. However, large-scale multicenter validation studies are still needed to establish standardized diagnostic protocols and to ensure the widespread clinical implementation.



Figure 1. Rapid Molecular Diagnostics and Biomarker-Based Sepsis Detection

The integrated approach for neonatal sepsis detection is shown in Figure 1. Blood drawn from neonates is simultaneously subjected to rapid molecular diagnostic testing and to analysis for biomarkers. We use molecular technology to identify the causative pathogen and biomarkers to assess inflammatory responses associated with infection. The integration of these techniques improves diagnostic precision, enables early recognition of sepsis and supports rapid initiation of treatment. Therefore, early intervention results in better clinical outcomes, less complications, and improved survival rates in neonates admitted to intensive care units.

3 Methodology

3.1 Research Design

The present study was a prospective observational study, to evaluate the advances in the diagnosis of neonatal sepsis with the help of rapid molecular diagnostic technologies and biomarkers. The study was carried out in the neonatal intensive care units (NICUs) of selected tertiary health care hospitals. Neonates suspected of having sepsis were followed-up from admission till discharge or completion of treatment. The design allowed evaluation of the diagnostic performance, time to detection and clinical outcomes of molecular diagnostic methods and biomarkerbased screening [12].

3.2 Study Population and Sample Selection

A total of 220 neonates with suspected sepsis admitted to NICUs were enrolled. Inclusion criteria were neonates of 0-28 days of age with clinical signs of infection including respiratory distress, temperature instability, feeding intolerance or lethargy. Neonates with congenital malformations or inherited metabolic diseases were excluded.

Table 1. Demographic Characteristics of Study Population

Variable	Value
Total Neonates	220
Male Neonates	118 (53.6%)
Female Neonates	102 (46.4%)
Preterm Neonates	92 (41.8%)
Term Neonates	128 (58.2%)
Confirmed Sepsis Cases	68 (30.9%)

3.3 Diagnostic Procedures

All the neonates enrolled were taken blood samples under sterile condition. Rapid molecular diagnostics such as polymerase chain reaction (PCR) and multiplex PCR assays were performed to detect bacterial and fungal pathogens. Biomarker analysis was performed including measurement of C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA) techniques. Conventional blood cultures were also performed for comparison [16].

Table 2. Diagnostic Parameters Evaluated

Parameter	Method
Pathogen Identification	PCR / Multiplex PCR
C-Reactive Protein (CRP)	ELISA
Procalcitonin (PCT)	ELISA
Interleukin-6 (IL-6)	ELISA
Blood Culture	Conventional Microbiology

3.4 Outcome Measures and Statistical Analysis

Main outcomes were diagnostic sensitivity, specificity, time to pathogen detection and time to treatment initiation. The secondary outcomes were the length of NICU stay, mortality and survival rates. Data were analysed using SPSS version 29. Descriptive statistics, chi-square tests, receiver operating characteristic (ROC) analysis and logistic regression models were used. We used $p < 0.05$ as the threshold for statistical significance [17].



Figure 2. Methodological Framework

The methodological framework used in the study is shown in Figure 2. Eligible neonates were recruited and blood samples were collected for molecular diagnostic testing and biomarker analysis. The pathogen was identified by PCR-based technologies and the inflammatory biomarkers were measured by laboratory assays. Results of the diagnostics were compared to clinical outcomes and standard blood culture results. Statistical analyses were then performed to assess the effectiveness of rapid molecular diagnostics and biomarkers in detection of neonatal sepsis and improvement of patient outcomes.

3.5 Dataset and Parameters

We included 220 neonates with suspected sepsis admitted to neonatal intensive care units (NICUs). Prospective collection of clinical, laboratory and microbiological data . Blood samples were tested by rapid molecular diagnostic methods such as polymerase chain reaction (PCR) and biomarker assays for C-reactive protein (CRP), procalcitonin (PCT) and interleukin-6 (IL-6). The results of conventional blood culture served as the reference standard. The experimental setup was used to compare the diagnostic accuracy, time to pathogen detection and clinical outcomes between rapid diagnostics and traditional methods. Statistical analysis using SPSS version 29 was performed to evaluate diagnostic performance [12, 16].

Table 3. Dataset and Experimental Setup

Parameter	Description
Total Neonates	220
Study Design	Prospective Observational Study
Study Setting	NICUs
Molecular Diagnostics	PCR, Multiplex PCR
Biomarkers	CRP, PCT, IL-6
Reference Standard	Blood Culture
Primary Outcomes	Sensitivity, Specificity, Detection Time
Analysis Software	SPSS Version 29

4 Results & Discussion

The findings of this study assess the usefulness of rapid molecular diagnostic technologies and biomarkers for early diagnosis of neonatal sepsis. Diagnostic accuracy, time to pathogen detection and clinical outcomes were assessed using data from 220 neonates admitted to NICUs. Molecular diagnostics combined with biomarker analysis showed significant improvements. The clinical value of integrated diagnostic approaches in the management of neonatal sepsis was shown by early pathogen identification, higher diagnostic sensitivity and improved survival rates.

4.1 Diagnostic Performance of Molecular Technologies and Biomarkers

Table 4. Diagnostic Accuracy of Different Methods

Diagnostic Method	Sensitivity (%)	Specificity (%)	Detection Time
Blood Culture	74.2	95.1	48–72 Hours
PCR-Based Assay	88.6	91.3	4.2 ± 1.1 Hours
Biomarker Panel (CRP+PCT+IL-6)	91.4	88.7	2.8 ± 0.9 Hours
Combined Molecular + Biomarker Approach	94.8	92.5	3.5 ± 0.8 Hours

When the molecular and biomarker approaches were combined, the best diagnostic performance was obtained (sensitivity 94.8%, specificity 92.5%). PCR-based assays drastically reduced the time to pathogen detection over conventional blood

cultures. Biomarker panels were rapidly and preliminarily evaluated and assisted early clinical decision making. These results suggest integrated diagnostic approaches improve the diagnosis of neonatal sepsis and reduce the time to initiation of treatment.



Figure 3. Comparison of Diagnostic Sensitivity

Figure 3 shows the sensitivity of various diagnostic approaches for the detection of neonatal sepsis. The combination of molecular and biomarker approaches showed the highest sensitivity, followed by biomarker panels and PCR based assays. The conventional blood culture was the least sensitive but is still the reference standard. The enhanced diagnostic capability of integrated strategies points to their value for the early detection of neonatal sepsis, which enables prompt treatment and reduces the likelihood of complications.

4.2 Clinical Outcomes and Treatment Efficiency

Table 5. Clinical Outcomes Following Early Sepsis Detection

Outcome Variable	Conventional Diagnosis	Rapid Diagnostic Approach
Mean Detection Time (Hours)	58.4 ± 8.2	3.5 ± 0.8
Antibiotic Initiation Delay (Hours)	12.6 ± 3.4	7.3 ± 2.1
Average NICU Stay (Days)	18.4 ± 4.2	13.1 ± 3.6
Survival Rate (%)	86.8	94.1

Rapid diagnostic technologies significantly enhanced clinical outcomes. The sooner the infection was identified, the sooner antibiotics were started—about 42% sooner—and babies spent more than five fewer days in the NICU, on average. Neonates diagnosed by rapid molecular and biomarker-based methods also had significantly higher survival rates. These results show that early diagnosis directly leads to better patient management and survival of the neonate.



Figure 4. Clinical Outcome Comparison

Figure 4 compares the survival outcomes between conventional diagnostic methods and rapid diagnostic approaches. Rapid molecular technologies and biomarker screening for diagnosis of neonates were associated with significantly higher survival rates than diagnosis by conventional methods alone. Early detection of the pathogen resulted in early antimicrobial therapy and improved clinical management. Consequently, rapid diagnostics led to decreased mortality, shorter hospitalizations, and overall improved health outcomes for neonates.

The study showed that rapid molecular diagnostic technologies and biomarker-based screening can significantly improve the detection of neonatal sepsis. The combined diagnostic approach showed the highest sensitivity and specificity and significantly reduced detection times. Early diagnosis led to early treatment, which meant better survival rates and shorter NICU stays. These findings support implementation of rapid molecular diagnostics and biomarkers in routine management of neonatal sepsis.

5 Conclusion

This study concludes that the rapid molecular diagnostic technologies and the biomarker-based approaches greatly enhance the early detection and management of neonatal sepsis. Molecular diagnostics enabled faster identification of pathogens and improved diagnostic accuracy compared to traditional blood culture methods. Biomarkers such as C-reactive protein (CRP), procalcitonin (PCT) and interleukin-6 (IL-6) were found to have a high predictive value for the early recognition of sepsis. The integrated molecular and biomarker method achieved the greatest sensitivity and specificity, allowing for early treatment and shorter diagnostic delay. Among neonates diagnosed by rapid diagnostic methods, better clinical outcomes in terms of shorter NICU stay and better survival rates were observed . Thus, the integration of these cutting-edge technologies into the routine neonatal care can improve the patient outcomes, optimize the antimicrobial therapy and reduce sepsis-related mortality.

References

[1] Shane AL, Sánchez PJ, Stoll BJ. Neonatal Sepsis. *The Lancet*. 2017.

[2] Iroh Tam PY, Bendel CM. Diagnostics for Neonatal Sepsis: Current Approaches and Future Directions. *Pediatric Research*. 2017.

[3] Pammi M, Flores A, Leeflang M. Molecular Assays for Diagnosis of Neonatal Sepsis. *Cochrane Database of Systematic Reviews*. 2011.

[4] Wynn JL, Wong HR. Pathophysiology and Diagnosis of Neonatal Sepsis. *Clinical Perinatology*. 2010.

[5] Jordan JA, Durso MB. Real-Time Polymerase Chain Reaction for Detection of Neonatal Bloodstream Infections. *Pediatrics*. 2010.

[6] Ng PC, Lam HS. Biomarkers for Late-Onset Neonatal Sepsis. *Current Opinion in Infectious Diseases*. 2012.

[7] Gilfillan M, Bhandari V. Neonatal Sepsis Biomarkers: Where Are We Now? *Research and Reports in Neonatology*. 2019.

[8] Cantey JB, Baird SD. Biomarker Combinations for Early Diagnosis of Neonatal Sepsis. *Journal of Perinatology*. 2020.

[9] Dong Y, Speer CP. Advances in the Diagnosis of Neonatal Sepsis. *Clinical Perinatology*. 2015.

[10] Hornik CP, Benjamin DK. Emerging Technologies in Neonatal Infection Diagnosis. *Seminars in Perinatology*. 2020.

[11] Stocker M, van Herk W, El Helou S. Modern Strategies for Neonatal Sepsis Diagnosis and Antimicrobial Stewardship. *Archives of Disease in Childhood Fetal and Neonatal Edition*. 2021.

[12] Pammi M, et al. Rapid Molecular Diagnostic Techniques for Neonatal Sepsis. *Frontiers in Pediatrics*. 2022.

[13] Coggins SA, et al. Advances in PCR-Based Detection of Neonatal Infections. *Clinical Microbiology Reviews*. 2023.

[14] Ng PC, et al. Biomarkers for Early-Onset Neonatal Sepsis: Current Evidence. *Pediatric Research*. 2022.

[15] Chauhan N, et al. Combined Biomarker Strategies for Neonatal Sepsis Diagnosis. *Journal of Neonatal-Perinatal Medicine*. 2023.

[16] Shane AL, et al. Integrated Molecular and Biomarker Approaches in Neonatal Sepsis Detection. *The Lancet Child & Adolescent Health*. 2024.

[17] Wynn JL, et al. Precision Diagnostics and Antimicrobial Stewardship in Neonatal Sepsis. *Nature Reviews Pediatrics*. 2025.

[18] Dong Y, Speer CP. Artificial Intelligence and Multi-Omics Approaches for Neonatal Sepsis Prediction. *Frontiers in Digital Health*. 2026